Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series [0.03%]
低风险骨髓增生异常综合征使用Luspatercept的现实世界单中心病例系列研究
Shamis Khan,Sara Taveras Alam,Rosa Torres Ramos et al.
Shamis Khan et al.
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia [0.03%]
布鲁顿酪氨酸激酶抑制剂在瓦尔登斯特伦巨球蛋白血症中的应用
Obada Ababneh,Hassan Abushukair,Aref Qarqash et al.
Obada Ababneh et al.
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström's Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generat...
Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine [0.03%]
在地西他滨治疗的骨髓增生异常背景下观察VEXAS综合征的临床、形态和克隆进展
Marco Manzoni,Alessandro Bosi,Sonia Fabris et al.
Marco Manzoni et al.
Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas [0.03%]
原发性皮肤γδT细胞淋巴瘤的临床、诊断和预后特征
Ibrahim N Muhsen,Riad El Fakih,Mehdi Hamadani et al.
Ibrahim N Muhsen et al.
Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare subtype of non-Hodgkin lymphoma (NHL) that arises from T-cells with γδ T-cell receptors. The exact incidence of PCGDTL is unknown, as it is usually lumped with other cutaneous lymp...
Invasive Fungal Rhinosinusitis Due to Co-infection with Mucormycosis and Exserohilum rostratum in a Patient with Acute Lymphoblastic Leukemia [0.03%]
一名急性淋巴细胞白血病患者并发毛霉菌和粗糙分支孢子菌的侵袭性真菌鼻窦炎
Vera Radici,Eolia Brissot,Suzanne Chartier et al.
Vera Radici et al.
Invasive fungal infections remain an important cause of complication and morbidity in the management of acute leukemias. Here we report the case of a 27-year-old patient from French Polynesia who was diagnosed with Philadelphia chromosome-n...
Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina [0.03%]
阿根廷经典霍奇金淋巴瘤一线治疗的多中心回顾性真实世界研究
Carolina Mahuad,Otero Victoria,Korin Laura et al.
Carolina Mahuad et al.
There are no data in Argentina on the response rates to first-line treatment of classical Hodgkin Lymphoma (cHL) outside clinical trials. A total of 498 patients from 7 public and private hospitals in Argentina were retrospectively examined...
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [0.03%]
新诊断慢性粒细胞性白血病患者从尼洛替尼换用伊马替尼的疗效和安全性：一项多中心开放标签随机研究
Ali Ibrahim,Nour Moukalled,Rami Mahfouz et al.
Ali Ibrahim et al.
The treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) with nilotinib has resulted in a higher rate of major molecular (MMR) and complete cytogenetic response (CCyR) at 12 months compared to imatinib but at a higher c...
Selected Domains within a Comprehensive Geriatric Assessment in Older Patients with Non-Hodgkin Lymphoma are Highly Associated with Frailty [0.03%]
全面老年评估的选定领域与非霍奇金淋巴瘤老年人的衰弱高度相关
María Del Pilar Gamarra Samaniego,Carmelo J Blanquicett,Roger V Araujo Castillo et al.
María Del Pilar Gamarra Samaniego et al.
Background: The incidence of Non-Hodgkin Lymphoma (NHL) is increasing, particularly among older patients who tend to have worse outcomes and can be predisposed to increased toxicities and less treatment tolerance. Therefo...
Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [0.03%]
急性白血病和骨髓瘤住院化疗趋势、费用和死亡率
Kellen Gil,Saqib Abbasi,Kathan Mehta et al.
Kellen Gil et al.
Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence? [0.03%]
免疫疗法和异基因骨髓移植在B细胞急性淋巴细胞白血病中的序贯应用？
Anna Komitopoulou,I Baltadakis,I Peristeri et al.
Anna Komitopoulou et al.
Long-term disease control is achieved in 80-90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse acco...